To close the existing gap in understanding the specific clinical characteristics of euDKA and hyDKA in patients with T2DM receiving SGLT2 inhibitors, we evaluated clinical characteristics of SGLT2 inhibitor-associated DKA, specifically focused on euDKA and hyDKA
Long-term or repeated use requires careful monitoring and proactive mitigation strategies
Through August 31, 2026, pay $149/month for the two lowest doses of Wegovy pills through a Novo Nordisk offer, subsequent doses are up to $299/month, restrictions and exclusions apply.** Through December 31, 2026, get first two months of Wegovy injectables for $199/month through an introductory Novo Nordisk offer, subsequent doses up to $349/month, restrictions and exclusions apply
Stay older people's rough muscle and keep bone mineral density and get proactive
Label vials with the reconstitution date for tracking purposes